Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer-BioNTech recipients. On average ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

The health secretary has chipped away at the idea that immunizing children against measles and other diseases is a public ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...

to develop bird flu vaccines over increasing fears of widespread transmission of the infection. Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, ...

The delay dovetails with moves by Republican lawmakers in at least 7 states to ban or limit mRNA vaccines. HealthDay News — The US Food and Drug Administration (FDA) has delayed the full ...

Full Food and Drug Administration approval would allow the vaccine to be used more widely and could offer more reassurance to people looking for options besides the existing mRNA vaccines.

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...